Vitaspring Biomedical Co., Ltd. balance sheet VSBC

Annual Quarterly

As of Jul 31, 2026, Vitaspring Biomedical Co., Ltd. had total assets of $14,822 and total liabilities of $4.7 million. Total assets were down 12.9% from a year earlier. Stockholders' equity was negative, at -$4.7 million, because liabilities exceed assets. Cash and investments were $13,367. The current ratio, current assets divided by current liabilities, was 0.01.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

Line	FY 2027 Jul 31, 2026	FY 2026 Jan 31, 2026	FY 2025 Jan 31, 2025	FY 2024 Jan 31, 2024	FY 2023 Jan 31, 2023	FY 2021 Jan 31, 2022	FY 2021 Jan 31, 2021	FY 2020 Jan 31, 2020	FY 2019 Jan 31, 2019	FY 2018 Jan 31, 2018
Assets
Cash	0 +1573.0%	0 +666.2%	0 +1992.3%	0 -100.0%	0	0	0	0 -100.0%	0 -98.0%	0
Cash and investments	0 +1573.0%	0 +666.2%	0 +1992.3%	0 -100.0%	0	0	0	0 -100.0%	0 -98.0%	0
Receivables	—	—	0	0 -100.0%	0	3	—	—	—	—
Inventory	—	—	—	—	0	—	0	—	—	—
Total current assets	0 +87.8%	0 +3770.2%	0 -98.8%	0 -94.6%	0	3	0	0 -100.0%	0 -9.2%	0
Property and equipment, net	0 -100.0%	0 -70.6%	0 -41.4%	0 -51.5%	0	0	—	—	0 -24.0%	0
Total assets	0 -12.9%	0 +2.1%	0 -89.5%	0 -82.1%	1	4	0	0	0 -100.0%	0
Liabilities and equity
Accounts payable	0 -100.0%	2 +0.0%	2 +0.0%	2 +0.0%	2	1	—	—	0 -100.0%	0
Total current liabilities	2 -46.3%	4 +10.3%	4 +15.5%	3 +13.6%	3	2	0	0 -100.0%	0 +12.5%	0
Total liabilities	5 +10.7%	4 +10.3%	4 +15.5%	3 +10.3%	3	2	0	0 -100.0%	0 -11.3%	0
Stockholders' equity	-5 -10.8%	-4 -10.3%	-4 -19.8%	-3 -39.8%	-2	2 +22900.1%	0 +1492.7%	—	-0 -102.4%	-0
Debt
Lease liabilities	—	0	0 -100.0%	0 +69.0%	0	0	—	—	—	—
Total debt	—	0	0 -100.0%	0 +69.0%	0	0	—	—	—	—
Net cash	—	0 +666.2%	0 +100.3%	-0 -265.0%	-0	-0	—	—	—	—
Ratios
Current ratio	0.01x	0.00x	0.00x	0.01x	0.14x	1.76x	2.04x	—	0.55x	0.68x
Debt to equity	—	—	—	—	—	0.30x	—	—	—	—
Debt to EBITDA	—	—	—	—	—	0.42x	—	—	—	—
Return on equity	—	—	—	—	—	57.66%	943.88%	—	—	—
Return on assets	-3,074.10%	-2,830.25%	-5,389.64%	-814.44%	-543.69%	25.24%	480.24%	—	—	-340.13%
Book value per share	-0.02	-0.02	—	—	-0.02	—	0.00	—	—	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. The first column is the latest balance sheet when it is newer than the latest fiscal year. More on our methodology.

Company profile

Industry: Services-Commercial Physical & Biological Research (SIC 8731)
Listed as: VSBC (OTC)
Fiscal year ends: January 31
Incorporated in: NV
Headquarters: Riverside, CA
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1697884
Former names: Shemn Corp. (until Apr 27, 2020)

Other Services-Commercial Physical & Biological Research companies

Iqvia Holdings Inc. IQV
Incyte Corp INCY
Medpace Holdings, Inc. MEDP
Charles River Laboratories International, Inc. CRL
Icon PLC ICLR
Absci Corp ABSI
OmniAb, Inc. OABI
NRC Health NRC

All 17 Services-Commercial Physical & Biological Research companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.